Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-07-15

Clinical Trial Update: Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial of Albendazole 400 mg tablets conducted in Chinese participants; results comparing pharmacokinetics were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Albendazole 400 mg tablets (Albendazole)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Helminthiasis | Phase 1 | Status: COMPLETED | Results posted: 2013-07-15